1. An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure

   • Swan Lin
   • Naveed Shaik
   • Ana Ruiz-Garcia

   Original Article Open access 03 September 2020 Pages: 451 - 459

   

2. Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib

   • Fan Wu
   • Gopal Krishna
   • Sekhar Surapaneni

   Original Article Open access 04 September 2020 Pages: 461 - 473

   

3. Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors

   • Keith T. Schmidt
   • Alwin D. R. Huitema
   • William D. Figg

   Original Article Open access 08 September 2020 Pages: 475 - 486

   

4. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer

   • Takahiro Tsushima
   • Hidefumi Kasai
   • Yusuke Tanigawara

   Original Article 15 September 2020 Pages: 487 - 495

   

5. Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer

   • Ludovic Fournel
   • Pascaline Boudou-Rouquette
   • Marco Alifano

   Original Article 16 September 2020 Pages: 497 - 505

   

6. Drug interactions with Bruton’s tyrosine kinase inhibitors: clinical implications and management

   • Karen M. Fancher
   • Jeremy J. Pappacena

   Original Article 17 September 2020 Pages: 507 - 515

7. Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms

   • Ryo Ariyasu
   • Noriko Yanagitani
   • Makoto Nishio

   Original Article 18 September 2020 Pages: 517 - 525

   

8. CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone

   • Stefania Crucitta
   • Marzia Del Re
   • Romano Danesi

   Original Article 18 September 2020 Pages: 527 - 533

   

9. Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker

   • Anand Joshi
   • Jianxia Guo
   • Jan H. Beumer

   Original Article 18 September 2020 Pages: 535 - 545

   

10. Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer

    • Christina Teng
    • Stephanie E. Reuter
    • Janette L. Vardy

    Original Article 19 September 2020 Pages: 547 - 558

    

11. Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction

    • Tomoko Morita-Ogawa
    • Hiroki Sugita
    • Kazuhiko Hanada

    Original Article 19 September 2020 Pages: 559 - 566

    

12. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers

    • Donghoon Shin
    • Yoon Jung Lee
    • Magdalena Petkova

    Clinical Trial Report Open access 19 September 2020 Pages: 567 - 575